FREE TRIAL

Get a FREE trial of The Wall Street Transcript and the Liberum Management Change Database.

Name

Company

Phone

E-mail
You are?


TWST Newsletter

Give us your email address and receive the TWST Newsletter.


Related Articles

Search TWST Online

Search by ticker:
or Sector:
Search by keyword:
See the latest Interview Excerpts

Subscribe to TWST

The Wall Stree Transcript is a completely unique resource for investors and business researchers. Thousands of in-depth interviews with CEOs, Industry Analysts and Professional Money Managers going back 10 years.

To obtain a copy of a TWST issue/report order online or call (212) 952-7433 .

SUBSCRIBE

Analyst Interview Excerpt
EMERGING GROWTH LIFE SCIENCES COMPANIES: KEAY NAKAE - C.E. UNTERBERG, TOWBIN


Full article published: 10/25/2005


For Subscribers

Get this article online now!

Order just this article
TWST: Would you give us some background on the conference? What is its focus?
Mr. Nakae: The focus of the conference is emerging growth life sciences and therefore the smaller cap names within that space. Most of the companies that will be presenting will have market caps anywhere in the range of 50 million to around 1 billion. We will also have a few private companies that are developing interesting products.

TWST: In general terms, what has gone on from a market perspective in that group so far this year?
Mr. Nakae: Within the medical device sector, the small cap group and the micro-cap group have had different performances. The small cap group, which I would classify as stocks with market caps between 200 million and 1 billion, has done well. The micro-cap group, which I would classify as stocks with a market cap under 200 million, has performed poorly this year.

 

Tickers included in this excerpt: AMMD, ANSI, BSX, CLN, CYBX, DBMI, ELOS, EPMD, GB, GDT, JNJ, LSCP, M, MDT, RITA, RTIX, SHMR, STJ, SYK, THOR, ULGX

 

For more information call (212) 952 7433. The Wall Street Transcript does not endorse any of the comments made by interviewees, and does not make stock recommendations.